Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
箕星药业
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Biotech/Healthcare
Jixing Pharmaceuticals (Jixing Yaoye) develops treatments for serious and life-threatening diseases. Its lead program is CK-274, a novel oral small-molecule cardiac myosin inhibitor for treating hypertrophic cardiomyopathy, licensed from Cytokinetics.
Latest round: Strategic (2026)
Source: ChinaBulls — chinabulls.com
Last updated 2026-10-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.